Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

被引：0
|
作者：
Nermine H. Zakaria
Doaa Hashad
Marwa H. Saied
Neamat Hegazy
Alyaa Elkayal
Eman Tayae
机构：
[1] University of Alexandria,Department of Clinical and Chemical Pathology, Faculty of Medicine
[2] University of Alexandria,Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine
来源：
Human Genomics | / 17卷
关键词：
HER2-positive breast cancer; Genetic variants; NGS; Trastuzumab; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] EVALUATION OF TRASTUZUMAB FOR ADJUVANT THERAPY OF HER2-POSITIVE BREAST CANCER EGYPTIAN FEMALES
    Abbas, N. A. R.
    ANNALS OF ONCOLOGY, 2010, 21 : 44 - 44
  • [32] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [33] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122
  • [34] Neoadjuvant trastuzumab in HER2-positive breast cancer, is pathological complete response enough?
    Ruvalcaba-Limon, Eva
    Pozo-Romero, Mariela
    Bautista-Pina, Veronica
    Tenorio-Torres, Alberto
    Morales-Vazquez, Flavia
    Rodriguez-Cuevas, Sergio
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 342 - 344
  • [35] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
  • [36] Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
    Derakhshani, Afshin
    Rezaei, Zohreh
    Safarpour, Hossein
    Sabri, Morteza
    Mir, Atefeh
    Sanati, Mohammad Amin
    Vahidian, Fatemeh
    Moghadam, Ali Gholamiyan
    Aghadoukht, Ali
    Hajiasgharzadeh, Khalil
    Baradaran, Behzad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) : 3142 - 3156
  • [37] Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients
    Visani, Luca
    Ratosa, Ivica
    Ribnikar, Domen
    Becherini, Carlotta
    Bertini, Niccolo
    Bonaparte, Ilaria
    Stefanovski, Dimitar
    Dobnikar, Nika
    Desideri, Isacco
    Olmetto, Emanuela
    Mangoni, Monica
    Di Cataldo, Vanessa
    Peruzzi, Anna
    Mattioli, Chiara
    Cela, Doruntina
    Valzano, Marianna
    Salvestrini, Viola
    Scoccimarro, Erika
    Livi, Lorenzo
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S691 - S692
  • [38] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [39] Prediction of Trastuzumab treatment response for HER2-positive breast cancer by microRNA profiling
    Sato, F.
    Wang, Z.
    Ueno, T.
    Myomoto, A.
    Takizawa, S.
    Masuda, N.
    Mikami, Y.
    Shimizu, K.
    Tsujimoto, G.
    Toi, M.
    CANCER RESEARCH, 2012, 72
  • [40] Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients
    Furrer, Daniela
    Jacob, Simon
    Michaud, Annick
    Provencher, Louise
    Lemieux, Julie
    Diorio, Caroline
    CLINICAL BREAST CANCER, 2018, 18 (04) : E687 - E694
12345